Who are CI-581-b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Lidocaine/Magnesium, Rémifentamil + KETAMINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ci-581-b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CI-581-b — Competitive Intelligence Brief

CI-581-b (CI-581-b) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist / Dissociative anesthetic. Area: Anesthesia / Psychiatry.

phase 3 NMDA receptor antagonist / Dissociative anesthetic NMDA receptor Anesthesia / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

CI-581-b (CI-581-b) — New York State Psychiatric Institute. CI-581-b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset anesthesia and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CI-581-b TARGET	CI-581-b	New York State Psychiatric Institute	phase 3	NMDA receptor antagonist / Dissociative anesthetic	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Rémifentamil + KETAMINE	Rémifentamil + KETAMINE	University Hospital, Clermont-Ferrand	marketed	Opioid + NMDA receptor antagonist combination	Mu-opioid receptor (remifentanil); NMDA receptor (ketamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist / Dissociative anesthetic class)

New York State Psychiatric Institute · 2 drugs in this class
Ullevaal University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CI-581-b — Competitive Intelligence Brief. https://druglandscape.com/ci/ci-581-b. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab